株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のPOC診断検査市場

Point of Care Diagnostic Testing World Markets

発行 TriMark Publications 商品コード 300948
出版日 ページ情報 英文 449 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
世界のPOC診断検査市場 Point of Care Diagnostic Testing World Markets
出版日: 2016年08月01日 ページ情報: 英文 449 Pages
担当者のコメント
TriMark Publicationsは、米国ニューヨークに本社を置く医療市場専門の調査会社です。なかでも、POCは同調査会社が最も注力している分野であり、世界市場に加え、アメリカ市場の分析に定評があります。比較的短いスパンで情報が更新されることから、最新データが網羅されているとして継続的に購入されるお客様が多いシリーズです。
概要

ポイントオブケア検査(POCT)は患者がポイントオブケア施設にいる間に即時に診断検査を実施できるだけでなく、これまで試験結果が出るまで数時間あるいは数日かかっていたところから結果をすぐに入手できるようになるものです。POCTには血糖値検査、血液ガス・電解質検査、妊娠検査、便潜血検査、食品病原菌検査、ヘモグロビン診断、感染症検査、コレステロール検査などに用いられています。

当レポートでは、ポイントオブケア検査(POCT)市場の最新動向について調査し、今後4年間の予測、地域別動向、および参入企業のプロファイルなどをまとめてお届けします。

第1章 概要

第2章 ポイントオブケア診断検査市場の概要

  • POC診断検査部門における主な問題点
    • 現在の市場動向と促進因子
    • POCTの効果
    • POCTの新たな成長分野
    • 臨床設備におけるPOCTの利点
    • 薬価および償還問題.
    • 主な顧客セグメント
  • 世界のポイントオブケア市場
  • 試験所検査からPOCTへの移行
  • 地域的分布
  • POCTの課題
  • POCTの主な問題点
    • POCTの場所
    • 技術開発のマイルストーン
    • 試験所から患者への分散化促進
    • 競合環境
  • 将来のPOCT

第3章 世界のPOCT市場のサマリー分析:価値、成長率、市場シェア

  • 世界のPOCT市場
  • 世界市場の収益;市場セグメント別
  • 世界市場シェア分析
  • 世界市場規模:地理的位置別
  • 世界市場規模:検体市場セグメント別
  • 世界のPOCT検査市場:場所別

第4章 米国のPOCT市場分析:価値、成長率、市場シェア

第5章 欧州のPOCT市場分析:価値、成長率、市場シェア

第6章 日本、中国、インドのPOCT市場分析:価値、成長率、市場シェア

  • 日本、中国、インドのPOCT市場:収益のサマリー分析
  • アジア(日本、インド、中国)市場収益分析:セグメント別
  • アジア市場シェア分析
  • 日本市場のサマリー分析
  • インド市場のサマリー分析
  • 中国市場のサマリー分析

第7章 世界のその他の諸国のPOCT市場分析:価値、成長率、市場シェア

  • 市場収益のサマリー分析
  • 市場収益のサマリー:市場セグメント別
  • 市場シェア分析
  • 市場収益のサマリー分析:国別

第8章 市場セグメント、試薬、設備の概要

第9章 POCT:成長規制因子

第10章 POCT分野におけるビジネス動向

第11章 POCTにおける技術プラットフォーム革新

第12章 データ管理と接続性

第13章 企業プロファイル

第14章 POCT分野の動向と予測

第15章 ポイントオブケア市場への新規参入企業

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TMRPOC16-0801

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. This TriMark Publications report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

Table of Contents

1. Overview

  • 1.1 About This Report
  • 1.2 Scope of the Report
  • 1.3 Objectives
  • 1.4 Methodology
  • 1.5 Executive Summary

2. Overview of Diagnostic Testing Point of Care Markets

  • 2.1 Key Issues in the POC Diagnostic Testing Sector
    • 2.1.1 Current Market Trends and Drivers
    • 2.1.2 Effectiveness of POCT
    • 2.1.3 New Growth Areas for POCT
    • 2.1.4 Advantages of POCT in a Clinical Setting
    • 2.1.5 Pricing and Reimbursement Issues
    • 2.1.6 Key Customer Segments
  • 2.2 Global Point of Care Marketplace
  • 2.3 Shifts from Central Lab Testing to POCT
  • 2.4 Geographical Distribution
  • 2.5 Challenges of POCT
  • 2.6 Key Issues for POCT
    • 2.6.1 Locations of POCT
    • 2.6.2 Milestones in Technology Development
    • 2.6.3 Drive for Decentralization from Lab to Patient
    • 2.6.4 Competitive Landscape for POCT
  • 2.7 The Future of POCT

3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share

  • 3.1 Global POCT Market
  • 3.2 Global Market Revenues Analysis by Market Segment
    • 3.2.1 Global POC Blood Glucose Monitoring Systems Market
    • 3.2.2 Global POC Blood Gas and Electrolyte Analyzers Market
    • 3.2.3 Global POC Rapid Coagulation Analyzers Market
    • 3.2.4 Global POC Cardiac Markers Devices Market
    • 3.2.5 Global POC Substance Abuse Testing Device Market
    • 3.2.6 Global POC Infectious Disease Testing Device Market
    • 3.2.7 Global POC Urine Strip Testing Market
    • 3.2.8 Global POC Pregnancy Testing Device Market
    • 3.2.9 Global POC Fecal Occult Device Market
    • 3.2.10 Global POC Cholesterol Testing Market
  • 3.3 Global Market Share Analysis
  • 3.4 Global Market Size by Geographic Location
  • 3.5 Global Market Size by Analyte Market Segment
  • 3.6 Global POCT Testing by Location

4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share

  • 4.1 U.S. Market Revenues Analysis by Market Segment
    • 4.1.1 U.S. POC Blood Glucose Monitoring Systems Market
    • 4.1.2 U.S. POC Blood Gas and Electrolyte Analyzers Market
    • 4.1.3 U.S. POC Rapid Coagulation Analyzers Market
    • 4.1.4 U.S. POC Cardiac Markers Devices Market
    • 4.1.5 U.S. POC Substance Abuse Testing Device Market
    • 4.1.6 U.S. POC Infectious Disease Testing Device Market
    • 4.1.7 U.S. POC Urine Strip Testing Market
    • 4.1.8 U.S. POC Pregnancy Testing Device Market
    • 4.1.9 U.S. POC Fecal Occult Device Market
    • 4.1.10 U.S. POC Cholesterol Testing Market
  • 4.2 U.S. Market Share Analysis
  • 4.3 U.S. Market Size by Analyte Market Segment

5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares

  • 5.1 European Market Revenues Analysis
  • 5.2 European Market Revenues Analysis by Geographic Region
    • 5.2.1 French Revenues for POCT Systems
    • 5.2.2 German Revenues for POCT Systems
    • 5.2.3 Italian Revenues for POCT Systems
    • 5.2.4 Spanish Revenues for POCT Systems
    • 5.2.5 U.K. Revenues for POCT Systems
    • 5.2.6 Benelux Revenues for POCT Systems
    • 5.2.7 Scandinavian Revenues for POCT Systems
    • 5.2.8 Rest of Europe Revenues for POCT Systems
  • 5.3 European Market Revenues Analysis by Market Segment
    • 5.3.1 European POC Blood Glucose Monitoring Systems Market
    • 5.3.2 European POC Blood Gas and Electrolyte Analyzers Market
    • 5.3.3 European POC Rapid Coagulation Analyzers Market
    • 5.3.4 European POC Cardiac Marker Market
    • 5.3.5 European POC Substance Abuse Testing Device Market
    • 5.3.6 European POC Infectious Disease Testing Market
    • 5.3.7 European POC Urine Strip Testing Market
    • 5.3.8 European POC Pregnancy Testing Device Market
    • 5.3.9 European POC Fecal Occult Blood Testing Market
    • 5.3.10 European POC Cholesterol Testing Market
  • 5.4 European Market Share Analysis

6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share

  • 6.1 Summary Analysis of Japanese, Chinese and Indian POCT Market Revenues
  • 6.2 Summary of Asian (Japanese, Chinese and Indian) Market Revenues by Market Segment
    • 6.2.1 Asian (Japanese, Chinese and Indian) POC Blood Glucose Monitoring Systems Market
    • 6.2.2 Asian (Japanese, Chinese and Indian) POC Blood Gas and Electrolyte Analyzers Market
    • 6.2.3 Asian (Japanese, Chinese and Indian) POC Rapid Coagulation Analyzers Market
    • 6.2.4 Asian (Japanese, Chinese and Indian) POC Cardiac Markers Devices Market
    • 6.2.5 Asian (Japanese, Chinese and Indian) POC Substance Abuse Testing Device Market
    • 6.2.6 Asian (Japanese, Chinese and Indian) POC Infectious Disease Testing Device Market
    • 6.2.7 Asian (Japanese, Chinese and Indian) POC Urine Strip Testing Market
    • 6.2.8 Asian (Japanese, Chinese and Indian) POC Pregnancy Testing Device Market
    • 6.2.9 Asian (Japanese, Chinese and Indian) POC Fecal Occult Device Market
    • 6.2.10 Asian (Japanese, Chinese and Indian) POC Cholesterol Testing Market
  • 6.3 Asian (Japanese, Chinese and Indian) Market Share Analysis
  • 6.4 Summary Analysis of the Japanese POCT Market
  • 6.5 Summary Analysis of the Indian POCT Market
  • 6.6 Summary Analysis of the Chinese POCT Market

7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share

  • 7.1 Summary Analysis of the ROW POCT Market Revenues
  • 7.2 Summary of the ROW Market Revenues by Market Segment
    • 7.2.1 ROW POC Blood Glucose Monitoring Systems Market
    • 7.2.2 ROW POC Blood Gas and Electrolyte Analyzers Market
    • 7.2.3 ROW POC Rapid Coagulation Analyzers Market
    • 7.2.4 ROW POC Cardiac Markers Devices Market
    • 7.2.5 ROW POC Substance Abuse Testing Device Market
    • 7.2.6 ROW POC Infectious Disease Testing Device Market
    • 7.2.7 ROW POC Urine Strip Testing Market
    • 7.2.8 ROW POC Pregnancy Testing Device Market
    • 7.2.9 ROW POC Fecal Occult Device Market
    • 7.2.10 ROW POC Cholesterol Testing Market
  • 7.3 ROW Market Share Analysis
  • 7.4 Summary Analysis of the ROW POCT Market Revenues
    • 7.4.1 Summary Analysis of the Argentinian POCT Market
    • 7.4.2 Summary Analysis of the Australian POCT Market
    • 7.4.3 Summary Analysis of the Brazilian POCT Market
    • 7.4.4 Summary Analysis of the Canadian POCT Market
    • 7.4.5 Summary Analysis of the Russian POCT Market
    • 7.4.6 Summary Analysis of the Middle East POCT Market
    • 7.4.7 Summary Analysis of the African POCT Market
    • 7.4.8 Summary Analysis of the Asia-Pacific POCT Market

8. Review of the Market Segments, Reagents and Equipment

  • 8.1 Blood Glucose Monitoring
    • 8.1.1 Introduction to Blood Glucose Monitoring
    • 8.1.2 Types of Blood Glucose Testing
      • 8.1.2.1 Fasting Blood Sugar (FBS) or Fasting Plasma Glucose (FPG)
      • 8.1.2.2 Two-Hour Postprandial Blood Sugar or Two-Hour PC
      • 8.1.2.3 Random Blood Sugar (RBS)
      • 8.1.2.4 Glucose Urine Test
      • 8.1.2.5 Blood Glucose Test Strip
      • 8.1.2.6 Glycosylated Hemoglobin (HbA1c)
      • 8.1.2.7 Intravenous Glucose Tolerance Test (IVGTT)
      • 8.1.2.8 Oral Glucose Tolerance Test (OGTT)
    • 8.1.3 Segmentation of POC Blood Glucose Testing
      • 8.1.3.1 Continuous Blood Glucose Monitoring (CBGM)
      • 8.1.3.2 Self-Monitoring Blood Glucose (SMBG) Testing
      • 8.1.3.3 Minimally-Invasive and Non-Invasive Blood Glucose Testing
      • 8.1.3.4 Emerging Glucose Monitoring Technologies
      • 8.1.3.5 Optical Transducer Technologies
      • 8.1.3.6 Transdermal Sensor Technologies
      • 8.1.3.7 Invasive Glucose Sensor Technologies
    • 8.1.4 Review of Professional POC Blood Glucose Monitoring Systems
      • 8.1.4.1 New Guidance: Use of Blood Glucose Monitoring Systems for Professional and Home POC
    • 8.1.5 Review of POC Blood Glucose Monitoring Products
      • 8.1.5.1 Abaxis, Inc.
      • 8.1.5.2 Abbott
      • 8.1.5.3 Alere
      • 8.1.5.4 Apex Biotechnology
      • 8.1.5.5 ARKRAY, Inc.
      • 8.1.5.6 DiaSys
      • 8.1.5.7 EKF Diagnostics
      • 8.1.5.8 Fora Care
      • 8.1.5.9 HemoCue (part of Radiometer)
      • 8.1.5.10 HMD BioMedical
      • 8.1.5.11 Infopia
      • 8.1.5.12 Instrumentation Laboratory
      • 8.1.5.13 Jant Pharmacal
      • 8.1.5.14 LifeHealth (formerly International Technidyne Corp.)
      • 8.1.5.15 Medtronic
      • 8.1.5.16 Nova Biomedical
      • 8.1.5.17 Polymer Technology Systems
      • 8.1.5.18 Radiometer
      • 8.1.5.19 Randox Laboratories
      • 8.1.5.20 Roche
      • 8.1.5.21 Siemens
      • 8.1.5.22 Stanbio Laboratory
      • 8.1.5.23 Techno Medica Co., Ltd.
      • 8.1.5.24 LifeScan
    • 8.1.6 Professional POC Hemoglobin A1c (HbA1c) Testing
      • 8.1.6.1 A. Menarini Diagnostics
      • 8.1.6.2 Alere
      • 8.1.6.3 Apex Biotechnology
      • 8.1.6.4 Convergent Technologies GmbH & Co.
      • 8.1.6.5 DiaSys Diagnostic Systems
      • 8.1.6.6 Diazyme Laboratories
      • 8.1.6.7 EKF Diagnostics
      • 8.1.6.8 Eurolyser
      • 8.1.6.9 Green Cross Medis (formerly Ceragem Medisys)
      • 8.1.6.10 HemoCue (a division of Radiometer)
      • 8.1.6.11 Infopia
      • 8.1.6.12 Roche
      • 8.1.6.13 SD Biosensor
      • 8.1.6.14 Siemens Healthcare Diagnostics
      • 8.1.6.15 Erba Diagnostics
    • 8.1.7 Market Analysis
      • 8.1.7.1 Worldwide Professional Glucose Testing Market
      • 8.1.7.2 U.S. Professional Glucose Testing Market
      • 8.1.8 Competitive Analysis for the Glucose POCT Sector
      • 8.1.9 Market Share for Glucose Testing
      • 8.1.10 Competitive Analysis for the Glucose POCT Sector
      • 8.1.11 Market Analysis
      • 8.1.11.1 Market Drivers
      • 8.1.11.2 Market Restraints
      • 8.1.12 POC Glucose Testing Assay Market and Technology Trends
      • 8.1.12.1 POC Glucose Testing Assay Market Trends
      • 8.1.12.2 POC Glucose Testing Assay Technology Trends
      • 8.1.12.3 POC Glucose Testing Assay Strategic Recommendations
  • 8.2 Blood Gas and Electrolytes
    • 8.2.1 Background to POC Blood Gas and Electrolyte Testing
      • 8.2.1.1 Acid-Base Balance and the Lungs
      • 8.2.1.2 Respiratory Acidosis
      • 8.2.1.3 Respiratory Alkalosis
      • 8.2.1.4 Metabolic (or Non-Respiratory) Acidosis
      • 8.2.1.5 Metabolic (or Non-Respiratory) Alkalosis
      • 8.2.1.6 Increasing Popularity of POC Blood Gas and Electrolyte Testing
    • 8.2.2 Market Segmentation (Segmentation by Type of Blood Gas Monitoring Equipment)
      • 8.2.2.1 Intermittent Blood Gas Monitoring Equipment
      • 8.2.2.2 Continuous Blood Gas Monitoring Equipment
      • 8.2.2.3 EABG Monitors
      • 8.2.2.4 IABG Monitors
      • 8.2.2.5 Portable Blood Gas Analyzers
      • 8.2.2.6 Patient-Attached On-Demand Blood Gas Analyzers
    • 8.2.3 Applications for POCT Blood Gas and Electrolyte Analyzers
    • 8.2.4 Emerging Technologies
    • 8.2.5 Whole-Blood Lactate
    • 8.2.6 Creatinine
    • 8.2.7 Electrolytes Point of Care Analysis: Comparison of POCT and Central Lab Results
    • 8.2.8 Review of Selected Blood Gas and Electrolyte Analyzers
    • 8.2.9 Review of Company Products
      • 8.2.9.1 Roche Corporation
      • 8.2.9.2 Siemens Healthcare Diagnostics
      • 8.2.9.3 Instrumentation Laboratory
      • 8.2.9.4 Nova Biomedical
      • 8.2.9.5 Radiometer
      • 8.2.9.6 Abbott Point of Care
      • 8.2.9.7 Accriva Diagnostics
      • 8.2.9.8 Alere
      • 8.2.9.9 Opti Medical
    • 8.2.10 Market Share for Blood Gas and Electrolyte Testing
    • 8.2.11 Market Analysis
      • 8.2.11.1 Market Drivers
      • 8.2.11.2 Market Restraints
    • 8.2.12 POC Blood Gas and Electrolyte Testing Assay Market and Technology Trends
      • 8.2.12.1 POC Blood Gas and Electrolyte Testing Assay Market Trends
      • 8.2.12.2 POC Blood Gas and Electrolyte Testing Assay Technology Trends
      • 8.2.12.3 POC Blood Gas and Electrolyte Testing Assay Strategic Recommendations
  • 8.3 Rapid Coagulation Tests
    • 8.3.1 Background to Rapid Coagulation Tests
    • 8.3.2 Review of Selected POC Rapid Coagulation Analyzers
    • 8.3.3 Review of Company Products
      • 8.3.3.1 Roche Diagnostics Corp.
      • 8.3.3.2 Abbott Laboratories
      • 8.3.3.3 Accriva
      • 8.3.3.4 Medtronic
      • 8.3.3.5 Alere
      • 8.3.3.6 Helena Laboratories Point of Care
      • 8.3.3.7 Sienco, Inc.
      • 8.3.3.8 Instrumentation Laboratory's GEM PCL Plus
    • 8.3.4 Connectivity Issues
    • 8.3.5 Cost Benefits
    • 8.3.6 Quality Control Issues
    • 8.3.7 Certification for POC Coagulation Devices
    • 8.3.8 D-Dimer Testing
    • 8.3.9 Market Analysis
      • 8.3.9.1 Market Share for POCT Coagulation Testing
      • 8.3.9.2 Competitive Analysis of Sector Companies
      • 8.3.9.3 Market Drivers
      • 8.3.9.4 Market Restraints
      • 8.3.9.5 POC Coagulation Testing Assay Market Trends
      • 8.3.9.6 POC Coagulation Testing Assay Technology Trends
      • 8.3.9.7 POC Coagulation Testing Assay Strategic Recommendations
      • 8.3.9.8 SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market
  • 8.4 POC Rapid Cardiac Markers
    • 8.4.1 Background to POC Rapid Cardiac Marker Testing
    • 8.4.2 Cardiac Marker Tests
      • 8.4.2.1 Creatine Kinase (CK)
      • 8.4.2.2 Myoglobin
      • 8.4.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC)
      • 8.4.2.4 C-Reactive Protein (CRP)
      • 8.4.2.5 Homocysteine
    • 8.4.3 Emerging Markers
      • 8.4.3.1 B-Type Natriuretic Peptide (BNP)
      • 8.4.3.2 Myeloperoxidase (MPO)
      • 8.4.3.3 Ischemia-Modified Albumin (IMA)
      • 8.4.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB)
      • 8.4.3.5 Fatty Acid-Binding Proteins (FABPs)
    • 8.4.4 Review of Selected POC Cardiac Biomarker Analyzers
    • 8.4.5 Review of Company Products
      • 8.4.5.1 Abbott's i-STAT System
      • 8.4.5.2 Alere's Triage System
      • 8.4.5.3 Alpha Scientific
      • 8.4.5.4 Boditech Med's i-CHROMA System
      • 8.4.5.5 BTNX
      • 8.4.5.6 Homemed
      • 8.4.5.7 LSI Medience (formerly Mitsubishi Chemical Medience Corp.)
      • 8.4.5.8 Nano-Ditech
      • 8.4.5.9 Princeton BioMeditech
      • 8.4.5.10 Radiometer (part of Danaher)
      • 8.4.5.11 Response Biomedical Corporation
      • 8.4.5.12 Roche Diagnostics' cobas h 232 POC System
      • 8.4.5.13 Roche's CARDIAC TROP T Sensitive Test (Visual)
      • 8.4.5.14 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, Diagnostic Products Corporation and Dade Behring)
      • 8.4.5.15 Trinity Biotech
      • 8.4.5.16 Trivitron Healthcare (formerly Ani Biotech)
      • 8.4.5.17 bioMérieux
    • 8.4.6 Market Share and Sales for Cardiac Marker Testing
      • 8.4.6.1 Market Drivers
      • 8.4.6.2 Market Restraints
    • 8.4.7 POC Cardiac Marker Testing Assay Market and Technology Trends
      • 8.4.7.1 POC Cardiac Marker Testing Assay Market Trends
      • 8.4.7.2 POC Cardiac Marker Testing Assay Technology Trends
      • 8.4.7.3 POC Cardiac Marker Testing Assay Strategic Recommendations
  • 8.5 POCT Substance Abuse Testing
    • 8.5.1 Background to POC Substance Abuse Testing
    • 8.5.2 Substance Abuse Test Types
      • 8.5.2.1 Urine Substance/Drug Screening
      • 8.5.2.2 Hair Tests for Substance Abuse and Screening
      • 8.5.2.3 Blood Tests for Substance Abuse and Screening
      • 8.5.2.4 Saliva Tests for Substance Abuse and Screening
      • 8.5.2.5 Sweat Tests for Substance Abuse and Screening
    • 8.5.3 Alcohol Abuse and Screening
    • 8.5.4 Saliva Testing
    • 8.5.5 Qualitative Analysis
      • 8.5.5.1 Market Drivers
      • 8.5.5.2 Market Restraints
    • 8.5.6 Review of Selected POC Substance Abuse Analyzers
    • 8.5.7 Review of Company Products
      • 8.5.7.1 Alere
      • 8.5.7.2 Abbott Diagnostics
      • 8.5.7.3 BTNX, Inc.
      • 8.5.7.4 BioScan Screening Systems, Inc.
      • 8.5.7.5 American Bio Medica Corp.
      • 8.5.7.6 Phamatech, Inc.
      • 8.5.7.7 First Check Diagnostics Corp. (Alere, Inc.)
      • 8.5.7.8 OraSure
      • 8.5.7.9 Noble Medical, Inc.
      • 8.5.7.10 Guangzhou Wondfo Biotech Co., Ltd.
      • 8.5.7.11 Pathtech
      • 8.5.7.12 Alfa Scientific Designs, Inc.
      • 8.5.7.13 American Bio Medica
      • 8.5.7.14 Biophor Diagnostics
      • 8.5.7.15 Randox Laboratories
      • 8.5.7.16 Branan Medical
      • 8.5.7.17 Concateno
      • 8.5.7.18 LifeSign
  • 8.6 POC Pregnancy and Fertility Tests
    • 8.6.1 Background to POC Pregnancy and Fertility Tests
    • 8.6.2 Review of Selected POC Pregnancy Testing Devices
    • 8.6.3 Review of Company Products
      • 8.6.3.1 Quidel
      • 8.6.3.2 Abbott Diagnostics
      • 8.6.3.3 Alere
      • 8.6.3.4 Sutherland Health Group Ltd.
      • 8.6.3.5 Sekisui Diagnostics, LLC
      • 8.6.3.6 Siemens Diagnostics
      • 8.6.3.7 Orgenics (A subsidiary of Alere)
      • 8.6.3.8 LifeSign
      • 8.6.3.9 Other Companies in this Sector
      • 8.6.3.10 Market Analysis
        • 8.6.3.10.1 Competitive Sector Analysis
  • 8.7 Fecal Occult Blood
    • 8.7.1 Background to POC Fecal Occult Blood Testing
    • 8.7.2 Review of Selected POC Fecal Occult Testing Devices
    • 8.7.3 Review of Company Products
      • 8.7.3.1 Helena Laboratories
      • 8.7.3.2 Biomerica
      • 8.7.3.3 Beckman Coulter
      • 8.7.3.4 Worldwide Medical
      • 8.7.3.5 Aerscher Diagnostics
      • 8.7.3.6 Enterix
      • 8.7.3.7 Medix Biochemica
      • 8.7.3.8 Orion Diagnostica
      • 8.7.3.9 ACON Laboratories' Mission FOB Reagent Strips
    • 8.7.3.10 Alere's Products
      • 8.7.3.11 Immunostics Hema-Screen
      • 8.7.3.12 Princeton BioMeditech's BioSign iFOBTest
      • 8.7.3.13 Quest Diagnostics' InSure FIT
      • 8.7.3.14 Quidel's QuickVue iFOB
      • 8.7.3.15 Exact Sciences' Cologuard
      • 8.7.3.16 Epigenomics
      • 8.7.3.17 CTK Biotech
    • 8.7.4 Market Share for Fecal Occult Blood Testing
      • 8.7.4.1 Company Analysis for the Fecal Occult Blood POCT Sector
    • 8.7.5 Market Analysis
      • 8.7.5.1 Market Drivers
      • 8.7.5.2 Market Restraints
      • 8.7.5.3 POC Fecal Occult Blood Testing Assay Market and Technology Trends
        • 8.7.5.3.1 POC Fecal Occult Blood Testing Assay Market Trends
        • 8.7.5.3.2 Fecal Occult Blood Testing Assay Technology Trends
        • 8.7.5.3.3 POC Fecal Occult Blood Testing Assay Strategic Recommendations
  • 8.8 POC Infectious Disease Testing
    • 8.8.1 Background to POC Infectious Disease Testing
    • 8.8.2 Types of Diagnosis for Infectious Diseases
      • 8.8.2.1 Microbial Culture
      • 8.8.2.2 Microscopy
      • 8.8.2.3 Biochemical Tests
      • 8.8.2.4 Immunologic Tests
      • 8.8.2.5 Molecular Diagnostics Testing
    • 8.8.3 Diagnostic Platforms for Infectious Diseases
      • 8.8.3.1 Centralized Laboratory Testing for Infectious Diseases
      • 8.8.3.2 POC Testing for Infectious Diseases
    • 8.8.4 Emerging Technologies
    • 8.8.5 Market Analysis
      • 8.8.5.1 Market Drivers
      • 8.8.5.2 Market Restraints
    • 8.8.6 Review of Selected POC Infectious Disease Testing Devices
      • 8.8.6.1 POC Infectious Disease Testing Devices and Assays in Development
        • 8.8.6.1.1 Cepheid's GeneXpert Omni
        • 8.8.6.1.2 Alere q
        • 8.8.6.1.3 Quidel
        • 8.8.6.1.4 Roche's cobas Liat System
        • 8.8.6.1.5 QuantuMDx's Q-POC
        • 8.8.6.1.6 SRI International
        • 8.8.6.1.7 Atlas Genetics' io System
    • 8.8.7 Overview of POC Assays for Detection of Infectious Disease
      • 8.8.7.1 Anthrax and Other Bio-threats
      • 8.8.7.2 Campylobacter
      • 8.8.7.3 Clostridium difficile
      • 8.8.7.4 E. coli
      • 8.8.7.5 Gastrointestinal Infectious Agents
        • 8.8.7.5.1 Giardia and Cryptosporidium
        • 8.8.7.5.2 Entamoeba histolytica
        • 8.8.7.5.3 Rotavirus & Adenovirus
        • 8.8.7.5.4 Norovirus
      • 8.8.7.6 Hepatitis
      • 8.8.7.7 Herpes Simplex Virus Type-2
      • 8.8.7.8 Influenza
      • 8.8.7.9 Legionella
      • 8.8.7.10 Malaria Testing
      • 8.8.7.11 Meningitis
      • 8.8.7.12 Mononucleosis
      • 8.8.7.13 Procalcitonin (Detects Sepsis)
      • 8.8.7.14 Respiratory Tract Infections
        • 8.8.7.14.1 C-Reactive Proteins
        • 8.8.7.14.2 Pneumonia
        • 8.8.7.14.3 Respiratory Tract Panels
      • 8.8.7.15 RSV
      • 8.8.7.16 Streptococcus
      • 8.8.7.17 Rubella
      • 8.8.7.18 Sexually-Transmitted Diseases
      • 8.8.7.18.1 Chlamydia
      • 8.8.7.18.2 Gonorrhea Testing
      • 8.8.7.18.3 Syphilis
      • 8.8.7.19 Staphylococcus aureus and MRSA
      • 8.8.7.20 Streptococcus A Testing
      • 8.8.7.21 Tropical Diseases
        • 8.8.7.21.1 Chagas Disease
        • 8.8.7.21.2 Dengue Fever
        • 8.8.7.21.3 Ebola
        • 8.8.7.21.4 Filariasis
        • 8.8.7.21.5 Onchocerciasis
        • 8.8.7.21.6 Zika Virus
      • 8.8.7.22 Tuberculosis
      • 8.8.7.23 Typhoid
  • 8.9 POC Urine Strip Testing
    • 8.9.1 Background to POC Urine Strip Testing
    • 8.9.2 Emerging Technologies
    • 8.9.3 Review of Selected POC Urine Strip Testing Devices
  • 8.10 POC Cholesterol Testing
    • 8.10.1 POC Cholesterol Testing Market Size and Development
    • 8.10.2 Background to POC Cholesterol Testing
    • 8.10.3 POC Cholesterol Testing Devices
      • 8.10.3.1 Review of Selected POC Cholesterol Testing Devices
    • 8.10.4 Review of Company Products
      • 8.10.4.1 Cholestech (Now Alere)
      • 8.10.4.2 Polymer Technology Systems
      • 8.10.4.3 Miraculins
      • 8.10.4.4 Abaxis, Inc.
    • 8.10.5 Product Comparison of Leading Suppliers
    • 8.10.6 Launch Dates of Leading Products Worldwide
  • 8.11 Miscellaneous POC Tests
    • 8.11.1 Estriol
    • 8.11.2 POC H. pylori Testing
    • 8.11.3 Bacterial Contamination of Platelet Units
    • 8.11.4 POC Vaginal Fluid pH and Vaginitis Testing
    • 8.11.5 POC Cancer Testing
      • 8.11.5.1 Prostate-Specific Antigen (PSA)
      • 8.11.5.2 Bladder Cancer
      • 8.11.5.3 Other Rapid Cancer Tests
    • 8.11.6 Fetal Status (PROM)
    • 8.11.7 Hemodynamic Monitoring
    • 8.11.8 Heparin-Induced Thrombocytopenia
    • 8.11.9 Ruptured Fetal Membranes
    • 8.11.10 Alcohol
    • 8.11.12 Microalbumin Testing
    • 8.11.13 Prenatal, Labor and Delivery Testing
    • 8.11.13.1 Alere Triage PLGF
    • 8.11.13.2 Medix Biochemica
    • 8.11.14 Sperm Fertility
    • 8.11.15 Surgical Coagulation and Hemostasis Management
    • 8.11.16 Respiratory Tests
    • 8.11.17 C-Reactive Protein
  • 8.12 HIV
    • 8.12.1 FDA-Approved Rapid HIV Assays
      • 8.12.1.1 Alere
      • 8.12.1.2 bioLytical Laboratories, Inc.
      • 8.12.1.3 Bio-Rad Laboratories
      • 8.12.1.4 Chembio Diagnostics
      • 8.12.1.5 MedMira Laboratories, Inc.
      • 8.12.1.6 OraSure Technologies
      • 8.12.1.7 Trinity Biotech
    • 8.12.2 Rapid HIV Assays Not Approved by the FDA (not commercially available in the U.S.)
      • 8.12.2.1 Alere
      • 8.12.2.2 bioMérieux
      • 8.12.2.3 Bio-Rad
      • 8.12.2.4 Core Diagnostics
      • 8.12.2.5 CTK Biotech
      • 8.12.2.6 EY Laboratories
      • 8.12.2.7 Hema Diagnostics Systems
      • 8.12.2.8 ImmunoScience
      • 8.12.2.9 InTec Products
      • 8.12.2.10 JAL Innovation
      • 8.12.2.11 J Mitra & Co.
      • 8.12.2.12 Premier Medical Corporation
      • 8.12.2.13 Princeton BioMeditech
      • 8.12.2.14 Savyon Diagnostics
      • 8.12.2.15 Shanghai Kehua
      • 8.12.2.16 Span Diagnostics
      • 8.12.2.17 Tulip Group
      • 8.12.2.18 YD Diagnostics' AIDScan
      • 8.12.3 POC Viral Load Technologies of the Future
      • 8.12.3.1 Cepheid
      • 8.12.3.2 Roche
      • 8.12.3.3 Wave 80 Biosciences

9. POCT: Growth Regulators

  • 9.1 Moderators of Growth
  • 9.2 Personnel Acceptance
  • 9.3 Key People for POCT
  • 9.4 Information Management Issues
    • 9.4.1 Elements of Information Management for POCT: Information-Processing Capabilities
    • 9.4.2 Data Mining
    • 9.4.3 Middleware
    • 9.4.4 Web Portals
    • 9.4.5 POCT-1A Standard
  • 9.5 Key Elements for POCT
  • 9.6 POCT and Reimbursement
  • 9.7 Effectiveness of Clinical Outcomes
  • 9.8 Rapid Near-Patient Testing in Hospitals
  • 9.9 Satellite Facilities
  • 9.10 Regionalization of Laboratory Care
  • 9.11 Requirements for POCT
  • 9.12 Locations of POC for Patient Care
  • 9.13 Benefits of POCT
  • 9.14 Cost Elements of POCT
  • 9.15 Necessary Functions in POCT
  • 9.16 Turnaround Time (TAT) for POCT
  • 9.17 Clinical Laboratory Improvement Amendments (CLIA)
  • 9.18 Sexually-Transmitted Diseases in Underdeveloped Countries
  • 9.19 Sources of Error in POC Testing

10. Business Trends in the POC Sector

  • 10.1 Sector Consolidation
  • 10.2 Diagnostic Testing Growth Trends
    • 10.2.1 Opportunities for Healthcare Stakeholders
  • 10.3 Acquisition, License Agreements, Internal Development and Partnerships
  • 10.4 Product Testing Depth in POCT
  • 10.5 Government Regulation
    • 10.5.1 U.S. Regulation
      • 10.5.1.1 Importing Medical Devices into the U.S.
      • 10.5.1.2 Exporting Medical Devices from the U.S.
    • 10.5.2 E.U. Regulation
    • 10.5.3 Japanese Regulation
  • 10.6 Post-Filing Regulations for POC Devices
  • 10.7 Exporting Unapproved POCTs
  • 10.8 Analyte-Specific Reagents ("Home-Brew" Tests)
  • 10.9 Medical Device Registration
  • 10.10 Product Labeling
  • 10.11 Punitive FDA Actions
  • 10.12 CLIA '88 and State Laboratory Laws
  • 10.13 Impact of Regulations on the Industry
  • 10.14 Minimizing Regulatory Barriers
  • 10.15 Waived Testing

11. Technology Platform Innovations in POCT

  • 11.1 Latest POCT Technological Platforms
    • 11.1.1 Device Miniaturization and Microfluidic Technologies
    • 11.1.2 Minimally-Invasive and Non-Invasive POCT Technologies
      • 11.1.2.1 Libre Flash Glucose Monitor and OneTouch Verio Sync Meter
      • 11.1.2.2 Echo Therapeutics
    • 11.1.3 Advances in Wireless Technologies
    • 11.1.4 Automation of POCT
    • 11.1.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies)
    • 11.1.6 Advances in Informatics Technologies
    • 11.1.7 Pharmacogenetic Testing
    • 11.1.8 Multi-Assay Technologies in POCT
    • 11.1.9 Molecular Diagnostic Technology in POCT for Infectious Disease
  • 11.2 Smart Phone Technology
    • 11.2.1 Aquila Diagnostic Systems, Inc.
    • 11.2.2 AgaMatrix
    • 11.2.3 Quick HIV and Syphilis Screening
    • 11.2.4 Accu-Check Connect System
  • 11.3 QuantuMDx Handheld, Portable Low Cost Rapid Devices

12. Data Management and Connectivity

  • 12.1 Wireless LANs
  • 12.2 Connectivity Platforms
    • 12.2.1 Data Management Systems
      • 12.2.1.1 Alere RALS System
      • 12.2.1.2 International Technidyne Corporation HEMOCHRON Signature Elite
      • 12.2.1.3 Siemens Diagnostics Rapidpoint
      • 12.2.1.4 Radiometer
      • 12.2.1.5 HemoCue's DM Hemoglobin
      • 12.2.1.6 Roche Diagnostics Cobas IT
      • 12.2.1.7 Accriva
    • 12.2.3 BD.id
    • 12.2.4 Medical Implant Communications Service (MICS)
    • 12.2.5 Conworx Technology
    • 12.2.6 Telcor QML
    • 12.2.7 Medasys
    • 12.2.8 NoemaLife
    • 12.2.9 Telcare
  • 12.3 Advantages of POCT Connectivity
    • 12.3.1 Cost-Benefit Analysis of POCT and IT Connectivity
    • 12.3.2 Hospital Network Issues

13. Corporate Profiles

  • 13.1 Abaxis, Inc.
  • 13.2 Abbott Laboratories
  • 13.3 AccuBioTech Co., Ltd.
  • 13.4 Accriva Diagnostics
  • 13.5 ACON Laboratories, Inc.
  • 13.6 Acrongenomics
  • 13.7 AgaMatrix
  • 13.8 Aerscher Diagnostics, LLC
  • 13.9 Akers Biosciences, Inc.
  • 13.10 Alere
  • 13.11 Alfa Scientific Designs, Inc.
  • 13.12 American Bio Medica Corporation
  • 13.13 Arkray, Inc.
  • 13.14 Atlas Genetics Ltd.
  • 13.15 Atonomics A/S
  • 13.16 Audit Diagnostics
  • 13.17 Augurix Diagnostics Ltd.
  • 13.18 Axxin
  • 13.19 Beckman Coulter (Danaher Corporation)
  • 13.20 bioLytical Laboratories
  • 13.21 Biomerica, Inc.
  • 13.22 bioMérieux
  • 13.23 BiOracle
  • 13.24 Bio-Rad Laboratories, Inc.
  • 13.25 BioScan Screening Systems, Inc.
  • 13.26 Calypte Biomedical Corporation
  • 13.27 Chembio Diagnostic, Inc.
  • 13.28 Cholestech
  • 13.29 Claros Diagnostics (OPKO Healthcare)
  • 13.30 ERBA Diagnostics, Inc.
  • 13.31 Daktari Diagnostics
  • 13.32 Dexcom
  • 13.33 Diagnostics for All
  • 13.34 Enigma Diagnostics Ltd.
  • 13.35 EY Laboratoires, Inc.
  • 13.36 Eurotrol
  • 13.37 Exalenz Bioscience
  • 13.38 GenBio
  • 13.39 Guided Therapeutics, Inc.
  • 13.40 Helena Laboratories
  • 13.41 Hema Diagnostic Systems, LLC
  • 13.42 Instrumentation Laboratory (IL)/Werfen Group
  • 13.43 Jant Pharmacal Corporation
  • 13.44 Lein Applied Diagnostics
  • 13.45 LifeSign, LLC
  • 13.46 Medica Corporation
  • 13.47 Medix Biochemica
  • 13.48 MedMira Laboratories
  • 13.49 A. Menarini Diagnostics
  • 13.50 Micronics
  • 13.51 New Horizons Diagnostics
  • 13.52 Nova Biomedical
  • 13.53 OraSure Technologies, Inc.
  • 13.54 Orion Diagnostica
  • 13.55 Polymedco, Inc.
  • 13.56 Polymer Technology Systems, Inc.
  • 13.57 Prima Biomedical Company
  • 13.58 Qualigen
  • 13.59 Quest Diagnostics, Inc.
  • 13.60 Quidel Corporation
  • 13.61 Radiometer Medical
  • 13.62 Response Biomedical Corp.
  • 13.63 Roche Diagnostics
  • 13.64 Savyon Diagnostics
  • 13.65 Seegene
  • 13.66 Sekisui Diagnostics, LLC
  • 13.67 Shanghai Ruicare Medical Co., Ltd.
  • 13.68 Shenzhen Fitconn Technology Co., Ltd.
  • 13.69 Shionogi & Co., Ltd.
  • 13.70 Siemens AG
  • 13.71 Siloam Biosciences, Inc.
  • 13.72 Spectral Diagnostics, Inc.
  • 13.73 StatSure Diagnostic Systems, Inc.
  • 13.74 One Step Detect Associates, LLC
  • 13.75 Senseonics
  • 13.76 Telcare
  • 13.77 Trinity Biotech Plc
  • 13.78 Väsamed, Inc.

14. POCT Sector Trends and Forecasts

  • 14.1 Home Care Analysis as Part of Near-Patient Testing
  • 14.2 Non-Traditional Collection for POCT
  • 14.3 New Systems for Critical Care and Near-Patient Testing
  • 14.4 Utility of Near-Patient Testing in Critical-Care Settings
  • 14.5 Physician's Office Market
  • 14.6 Information Management Advances
  • 14.7 Test-Ordering Patterns and Demand for POCT
  • 14.8 Demand for Emergency Department Services
  • 14.9 Move Away from the Central Laboratory
  • 14.10 Healthcare Cost Controls
  • 14.11 Mergers & Acquisitions
  • 14.12 Competition for Services
  • 14.13 Drivers of POCT
  • 14.14 Confluence of New Technology
  • 14.15 Difficulties of Design for POC Products
  • 14.16 Point of Care Compliance
  • 14.17 The Biggest New Opportunities in POCT

15. New Entrants to the Point of Care Market

  • 15.1 Alliance International Co., Ltd.
  • 15.2 Analyticon Biotechnologies AG
  • 15.3 Ativa Medical Corporation
  • 15.4 Aquila Diagnostic Systems, Inc.
  • 15.5 ArcDia International Oyo Ltd.
  • 15.6 Artron Laboratories, Inc.
  • 15.7 Atlas Link Biotech Co., Ltd.
  • 15.8 Audit Diagnostics
  • 15.9 Autobio Diagnostics Co., Ltd.
  • 15.10 Biocartis SA
  • 15.11 BioFire Diagnostics, Inc.
  • 15.12 BioMedomics
  • 15.13 Biosensia Ltd.
  • 15.14 Curetis AG
  • 15.15 DxNA, LLC
  • 15.16 Echo Therapeutics, Inc.
  • 15.17 Gentag, Inc.
  • 15.18 Great Basin Corporation
  • 15.19 Immunexpress Group
  • 15.20 Integrated Diagnostics
  • 15.21 Integrity Applications
  • 15.22 MBio Diagnostics, Inc.
  • 15.23 Menssana Research, Inc.
  • 15.24 Metaara Medical Technologies, Inc.
  • 15.25 QuantuMDx Group
  • 15.26 Venaxis, Inc.
  • 15.27 Philips Business Group EBA
  • 15.28 Wave 80 Biosciences
  • 15.29 Veredus Laboratories Pte Ltd.

INDEX OF FIGURES

  • Figure 2.1: Worldwide Distribution of IVD Testing, 2015
  • Figure 2.2: Top 13 Country IVD Testing Markets, 2015
  • Figure 2.3: Market Share for IVD Testing by Company, 2015
  • Figure 3.1: Total Global POCT Market, 2008-2018
  • Figure 3.2: Worldwide Distribution of POCT, 2015
  • Figure 3.3: Summary of Global POCT Markets by Market Segment, 2015
  • Figure 4.1: U.S. Revenues for POCT Market, 2008-2018
  • Figure 4.2: Summary of U.S. POCT Markets by Market Segment, 2015
  • Figure 5.1: European Revenues for POCT Market, 2008-2018
  • Figure 6.1: Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018
  • Figure 6.2: Japanese Revenues for POCT Market, 2008-2018
  • Figure 6.3: Indian Revenues for POCT Market, 2008-2018
  • Figure 6.4: Chinese Revenues for POCT Market, 2008-2018
  • Figure 7.1: Summary Analysis of ROW POCT Market, 2008-2018
  • Figure 7.2: Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018
  • Figure 7.3: Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018
  • Figure 7.4: Summary Analysis of African Revenues for POCT Products Market, 2008-2018
  • Figure 7.5: Summary Analysis of Latin America Revenues for POCT Products Market, 2008-2018
  • Figure 8.1: Global Share of Glucose Testing Market by Company, 2015
  • Figure 8.2: Global POCT Share of Blood Gas and Electrolyte Testing Market, 2015
  • Figure 8.3: Global POCT Share of Coagulation Testing Market, 2015
  • Figure 8.4: Global POCT Share of Cardiac Marker Testing Market, 2015
  • Figure 8.5: Distribution of Infectious Diseases Tested at the Point of Care 259
  • Figure 8.6: Global POCT Share of HIV Testing Market, 2015
  • Figure 9.1: Annual Rate of Emergency Room Visits by Primary Expected Source of Payment
  • Figure 10.1: Conformity Assessment Route, Annexes and Quality System Standards by IVD Device Category 360
  • Figure 12.1: The Alere RALS Data Management System Connects to Most of the Major Instruments Used in Point of Care

INDEX OF TABLES

  • Table 2.1: Summary of Global POCT Markets by Major Market Sub-Segment, 2015 and 2018
  • Table 2.2: Summary of U.S. POCT Markets by Major Market Sub-Segment, 2015 and 2018
  • Table 2.3: Summary of European POCT Markets by Major Market Sub-Segment, 2015 and 2018
  • Table 2.4: Summary of Asian POCT Markets by Major Market Sub-Segment, 2015 and 2018
  • Table 2.5: Summary of ROW POCT Markets by Major Market Sub-Segment, 2015 and 2018
  • Table 2.6: Worldwide Distribution of IVD Testing, 2015
  • Table 2.7: Top 13 Country IVD Testing Markets, 2015
  • Table 2.8: Company Market Share for IVD Testing Markets, 2015
  • Table 2.9: Competitive Landscape for POC Diagnostic Testing 42
  • Table 3.1: Total Global POCT Market, 2008-2018
  • Table 3.2: Global Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
  • Table 3.3: Global Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
  • Table 3.4: Global Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
  • Table 3.5: Global Revenues for POC Cardiac Marker Devices, 2008-2018
  • Table 3.6: Global Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
  • Table 3.7: Global Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
  • Table 3.8: Global Revenues for POC Urine Strip Testing Products Market, 2008-2018
  • Table 3.9: Global Revenues for POC Pregnancy Testing Devices Market, 2008-2018
  • Table 3.10: Global Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
  • Table 3.11: Global Revenues for POC Cholesterol Testing Products Market, 2008-2018
  • Table 3.12: Global POCT Market Share Analysis, 2015
  • Table 3.13: Worldwide POCT Market Size by Geographic Location, 2008-2018
  • Table 3.14: Worldwide Distribution of POCT, 2015
  • Table 3.15: Summary of Global POCT Markets by Market Segment, 2015
  • Table 3.16: Worldwide POCT by Performance Location, 2015
  • Table 4.1: U.S. Revenues for POCT Market, 2008-2018
  • Table 4.2: U.S Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
  • Table 4.3: U.S. Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
  • Table 4.4: U.S. Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
  • Table 4.5: U.S. Revenues for POC Cardiac Marker Devices, 2008-2018
  • Table 4.6: Market Share of U.S. POCT Cardiac Marker Market, 2015
  • Table 4.7: U.S. Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
  • Table 4.8: U.S. Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
  • Table 4.9: U.S. Revenues for POC Urine Strip Testing Products Market, 2008-2018
  • Table 4.10: U.S. Revenues for POC Pregnancy Testing Devices Market, 2008-2018
  • Table 4.11: U.S. Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
  • Table 4.12: U.S. Revenues for POC Cholesterol Testing Products Market, 2008-2018
  • Table 4.13: U.S. POCT Market Share Analysis, 2015
  • Table 4.14: Summary of U.S. POCT Markets by Market Segment, 2015
  • Table 5.1: Models of Public-Private Partnership in Hospital Provision
  • Table 5.2: European Revenues for POCT Market, 2008-2018
  • Table 5.3: French Revenues for POCT Systems, 2008-2018
  • Table 5.4: German Revenues for POCT Systems, 2008-2018
  • Table 5.5: Italian Revenues for POCT Systems, 2008-2018
  • Table 5.6: Spanish Revenues for POCT Systems, 2008-2018
  • Table 5.7: U.K. Revenues for POCT Systems, 2008-2018
  • Table 5.8: Benelux Revenues for POCT Systems, 2008-2018
  • Table 5.9: Scandinavian Revenues for POCT Systems, 2008-2018
  • Table 5.10: Rest-of-Europe Revenues for POCT Systems, 2008-2018
  • Table 5.11: European Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
  • Table 5.12: European Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
  • Table 5.13: European Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
  • Table 5.14: European Revenues for POC Cardiac Markers, 2008-2018
  • Table 5.15: European Revenues for POC Substance/Drug Abuse Testing Market, 2008-2018
  • Table 5.16: European Revenues for POC Infectious Disease Testing Market, 2008-2018
  • Table 5.17: European Revenues for POC Urine Strip Testing Products Market, 2008-2018
  • Table 5.18: European Revenues for POC Pregnancy Testing Market, 2008-2018
  • Table 5.19: European Revenues for POC Fecal Occult Blood Testing Market, 2008-2018
  • Table 5.20: European Revenues for POC Cholesterol Testing Products Market, 2008-2018
  • Table 5.21: European Market Share Analysis, 2015
  • Table 6.1: Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018
  • Table 6.2: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
  • Table 6.3: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
  • Table 6.4: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
  • Table 6.5: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cardiac Marker Devices, 2008-2018
  • Table 6.6: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
  • Table 6.7: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
  • Table 6.8: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Urine Strip Testing Products Market, 2008-2018
  • Table 6.9: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Pregnancy Testing Devices Market, 2008-2018
  • Table 6.10: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
  • Table 6.11: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cholesterol Testing Products Market, 2008-2018
  • Table 6.12: Summary Analysis of Japanese, Chinese and Indian Market Shares, 2015
  • Table 6.13: Japanese Population and Aging Demographics Forecast, 2000-2050
  • Table 6.14: Japanese Revenues for POCT Market, 2008-2018
  • Table 6.15: Indian Revenues for POCT Market, 2008-2018
  • Table 6.16: Chinese Revenues for POCT Market, 2008-2018
  • Table 7.1: Summary Analysis of ROW POCT Market, 2008-2018
  • Table 7.2: Summary Analysis of ROW Revenues for POC Blood Glucose Monitoring Systems, 2008-2018
  • Table 7.3: Summary Analysis of ROW Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018
  • Table 7.4: Summary Analysis of ROW Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018
  • Table 7.5: Summary Analysis of ROW Revenues for POC Cardiac Marker Devices, 2008-2018 Table 7.6: Summary Analysis of ROW Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018
  • Table 7.7: Summary Analysis of ROW Revenues for POC Infectious Disease Testing Devices Market, 2008-2018
  • Table 7.8: Summary Analysis of ROW Revenues for POC Urine Strip Testing Products Market, 2008-2018
  • Table 7.9: Summary Analysis of ROW Revenues for POC Pregnancy Testing Devices Market, 2008-2018
  • Table 7.10: Summary Analysis of ROW Revenues for POC Fecal Occult Testing Devices Market, 2008-2018
  • Table 7.11: Summary Analysis of ROW Revenues for POC Cholesterol Testing Products Market, 2008-2018
  • Table 7.12: Summary Analysis of ROW Market Shares, 2015
  • Table 7.13: Summary Analysis of Argentinian Revenues for POCT Products Market, 2008-2018
  • Table 7.14: Summary Analysis of Australian Revenues for POCT Products Market, 2008-2018
  • Table 7.15: Summary Analysis of Brazilian Revenues for POCT Products Market, 2008-2018
  • Table 7.16: Summary Analysis of Canadian Revenues for POCT Products Market, 2008-2018
  • Table 7.17: Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018
  • Table 7.18: Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018
  • Table 7.19: Summary Analysis of African Revenues for POCT Products Market, 2008-2018
  • Table 7.20: Summary Analysis of Asia (Other) Revenues for POCT Products Market, 2008-2018
  • Table 7.21: Summary Analysis of Latin America (Other) Revenues for POCT Products Market, 2008-2018
  • Table 8.1: Selected POC Blood Glucose and Blood Gas Meters Marketed for Professional Use, 2015
  • Table 8.2: POC HbA1c Testing Devices and Assays on the Market
  • Table 8.3: Global Revenues for Total Professional Blood Glucose Monitoring (Central Laboratory Testing and Hospital POC and POL), 2013-2019
  • Table 8.4: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point of Care Market
  • Table 8.5: Global Share of Glucose Testing Market by Company, 2015
  • Table 8.6: Selected POC Blood Gas and Electrolyte Analyzers, 2015
  • Table 8.7: Market Share of Blood Gas and Electrolyte POCT Diagnostic Testing Companies Worldwide, 2015 168
  • Table 8.8: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Blood Gas and Electrolyte POC Market
  • Table 8.9: Hospital Locations of Point of Care Coagulation Testing
  • Table 8.10: Selected POC Rapid Coagulation Analyzers, 2015
  • Table 8.11: Actalyke XL
  • Table 8.12: Actalyke Mini
  • Table 8.13: Connectivity Modes for Leading Coagulation POCT Analyzers
  • Table 8.14: Market Share for Coagulation POCT Diagnostic Testing Companies, 2015
  • Table 8.15: Drivers for Point of Care Coagulation Testing
  • Table 8.16: Barriers for Point of Care Coagulation Testing
  • Table 8.17: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market
  • Table 8.18: Selected POC Cardiac Biomarkers, 2016
  • Table 8.19: Market Share of Cardiac Marker POCT Diagnostic Testing Companies Worldwide, 2015
  • Table 8.20: POC Cardiac Marker Testing Market: Market Drivers Ranked in Order of Impact
  • Table 8.21: POC Cardiac Marker Testing Market: Market Restraints Ranked in Order of Impact
  • Table 8.22: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Cardiac Marker POC Market
  • Table 8.23: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department
  • Table 8.24: Stat Urine Testing Drug Recommendations
  • Table 8.25: Selected POC Substance/Drug Abuse Testing Devices, 2016
  • Table 8.26: Selected POC Pregnancy Testing Devices, 2016
  • Table 8.27: Selected POC Fecal Occult Testing Devices, 2016
  • Table 8.28: ColoCARE Fecal Occult Blood Test
  • Table 8.29: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Fecal Occult Blood POC Market
  • Table 8.30: Selected POC Infectious Disease Testing Devices and Assays, 2016
  • Table 8.31: Influenza Diagnostic Rapid Tests
  • Table 8.32: Selected POC Urine Strip Testing, 2016
  • Table 8.33: Selected POC Cholesterol Testing Devices, 2016
  • Table 8.34: AmniSure
  • Table 8.35: Competitive Factors Related to HIV Tests
  • Table 8.36: Global POCT Market for Rapid HIV Testing, 2011-2020
  • Table 8.37: Global POCT Share of HIV Testing Market, 2015
  • Table 8.38: Rapid HIV Immunoassay Tests
  • Table 9.1: POCT1-Compliant Connectivity POC Instruments
  • Table 9.2: POCT Clinical Outcomes in Diabetic Ketoacidosis
  • Table 9.3: POCT Clinical Outcomes in Arterial Blood-Gas Measurements
  • Table 9.4: POCT in Three Hospitals-Cost Analysis with Labor Included
  • Table 9.5: POCT versus Central Lab-Cost Analysis for Glucose Testing
  • Table 11.1: Common Genotype Techniques
  • Table 12.1: Applications for Wireless LAN Technology
  • Table 12.2: Customized Reports Must Support CAP and JCAHO Requirements
  • Table 14.1: Improvements in Achieving ED Operational Efficiency Using POCT
  • Table 14.2: Test Menu and TAT for ED
  • Table 14.3: Top Reasons Why POC Cardiac Marker Testing is Implemented in the ED
  • Table 14.4: Key Areas and Metrics that Hospitals Measure to Assess Efficiency of ED
  • Table 14.5: Estimates of Patient Costs by DRG
Back to Top